Accueil Ernstrade Bourse Actualite Stock

plus500

London Stock Exchange (AZM )

Alizyme is a biopharmaceutical company, based in Cambridge, UK, targeting the treatment and management of gastrointestinal disorders, obesity and diabetes. It has a portfolio of products under development, which in addition to renzapride includes COLAL-PRED™ (Phase III for the management of ulcerative colitis), ATL-962 (completed Phase IIb for obesity) and ATL-104 (completed Phase I for mucositis). At the appropriate time Alizyme intends to license products to established pharmaceutical companies, who would complete development, gain marketing approval and commercialise the products.

http://www.alizyme.com

 


Copyright  2008  Ernstrade.com